Overview

Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function

Status:
Completed

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the effect of various degrees of hepatic function on the pharmacokinetics and safety of ALKS 5461.

Phase:

Phase 1

Details

Lead Sponsor:

Alkermes, Inc.